Conbercept Ophthalmic Injection

indicated for the treatment of wet age-related macular degeneration (wet AMD) that functions by blocking VEGF-family proteins. Highlights: 1, Patent-granted countries : US, EU, Japan, Russia, Canada, South Korea, India, Austria and China 2, More completed target, higher efficacy, more outstanding vision improvement, lower administration frequency than Ranibizumab; 3, Recorded by WHO in the 67th list of Recommended INNs; 4, Time to market: 2013 5, Global sales of originator Lucentis: 3700 million US Dollars in 2012; 6, International competitor: Lucentis Ranibizumab® by Genentech (Roche). Registration Dossiers:non-clinical & clinical part, drug substance part and drug product part.